Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4446227 | 0.78 | ALDH1A1 (0.41) | MEN1KMT2AALDH1A1 | |
| SCHEMBL9432085 | 0.77 | CYP1A2 (0.53) | CYP1A2MEN1KMT2AALDH1A1HTT | |
| SCHEMBL31490074 | 0.74 | ALDH1A1 (0.47) | CYP1A2MEN1KMT2AALDH1A1HTT | |
| SCHEMBL22119900 | 0.74 | ALDH1A1 (0.47) | CYP1A2MEN1KMT2AALDH1A1HTT | |
| SCHEMBL9290484 | 0.74 | CYP1A2 (0.41) | CYP1A2MEN1KMT2AALDH1A1HTT | |
| SCHEMBL12599922 | 0.74 | CYP1A2 (0.41) | CYP1A2MEN1KMT2AALDH1A1HTT | |
| SCHEMBL16092619 | 0.74 | CYP1A2 (0.48) | CYP1A2MEN1KMT2AALDH1A1HTT | |
| SCHEMBL22120070 | 0.74 | CYP1A2 (0.38) | CYP1A2MEN1KMT2AHTT | |
| SCHEMBL16247844 | 0.72 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL61643 | 0.71 | KDM4E (0.40) | CYP1A2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663936-B1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-20050176721-A1 | 2,5-Diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylprimidines | HUANG JIANHUA (US) | 2005-08-11 | — | — | US | disclosed |
| US-6887875-B2 | Bind with high selectivity and/ or high affinity to CRF1 receptors (Corticotropin Releasing Factor 1 Receptors), useful for treating psychiatric and neurological diseases, including depression, anxiety and post trauma stress | NEUROGEN CORPORATION (US) | 2005-05-03 | — | — | US | disclosed |
| EP-1399428-A1 | 2,5-DIARYLPYRAZINES, 2,5-DIARYLPYRIDINES AND 2,5-DIARYLPYRIMIDINES AS CRF1 RECEPTOR MODULATORS | Neurogen Corporation (US) | 2004-03-24 | — | — | EP | disclosed |
| US-20030119844-A1 | 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines | NEUROGEN CORPORATION | 2003-06-26 | — | — | US | disclosed |
| WO-2002100838-A1 | 2,5-DIARYLPYRAZINES, 2,5-DIARYLPYRIDINES AND 2,5-DIARYLPYRIMIDINES AS CRF1 RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119844-A1 | 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines | CRHR2, CRHR1, CRH | CYP1A2 1450/4885MEN1 1658/4885KMT2A 3666/4885 |
| US-20050176721-A1 | 2,5-Diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylprimidines | CRHR2, CRHR1, CRH | CYP1A2 1413/4885MEN1 1516/4885KMT2A 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.